147results about "Enzymology" patented technology

Provided herein are methods for capturing an analyte from a first region of interest of a biological sample on a substrate, where the biological sample comprises the first region of interest and a second region, and where the method includes contacting the second region with a sealant in order to create a hydrophobic seal thereby preventing an interaction between an analyte from the second region with a capture domain of a capture probe.

Provided herein are methods for capturing an analyte from a first region of interest of a biological sample on a substrate, where the biological sample comprises the first region of interest and a second region, and where the method includes contacting the second region with a sealant in order to create a hydrophobic seal thereby preventing an interaction between an analyte from the second region with a capture domain of a capture probe.

A reagent kit, staining method, and application for combining dual immunohistochemistry with elastin fiber staining. The reagent kit includes a combination of primary antibodies, consisting of anti-CK7 and anti-CD34 monoclonal antibodies from different species, such as rabbit anti-human CK7 monoclonal antibody and mouse anti-human CD34 monoclonal antibody. By selecting CK7 and CD34 as the primary antibody combination, the growth pattern of tumor epithelium can be accurately indicated, and the proliferation and thickening of alveolar septal fibrous tissue caused by tumors can be clearly revealed, as opposed to structural changes of alveoli induced by other factors. Combined with independent Victoria blue staining, the elastin fibers of the walls of arteries and veins, as well as the pleura of the lungs, can be clearly visualized, aiding in the assessment of the integrity of elastin fibers on the lung surface and in determining the extent of tumor infiltration.

Method for single molecule localization microscopy (SMLM) based on conventional fluorescent binder probes, including primary or secondary antibodies, that are applied in a gradual stepwise fashion to a fixed biological sample. In each step of the process, a low dose of the probe is applied in solution to the fixed biological sample to sparsely label target epitopes followed by sample washing to remove the free probe. The remaining bound fluorescent probes that are sparsely distributed over the sample are then imaged until they are photobleached. The high light collection efficiency from each probe in this approach (limited only by photobleaching) enables few Ångstrom lateral resolution and few nm axial resolution. Photobleaching of the probes at the end of each step generates a clean slate for application of the next step in the process, as well as the possibility for applying one or more probes in a consecutive fashion to the same sample for serial SMLM.

The invention discloses a skeletal muscle repair method and system based on muscle satellite cell regulation and control. The method comprises the following steps: performing proliferation and differentiation correlation analysis on satellite cell steady state data and aerobic exercise intensity data to establish a proliferation regulation and control map; determining a collaborative repair time window according to the atlas, extracting difference response deviation correction parameters to form an activity correction factor, and performing repair intensity correction on the collaborative repair time window to generate a self-adaptive repair window; carrying out exercise prescription adaptation on the self-adaptive repair window, identifying a satellite cell activation regulation and control channel, obtaining activation delay time through activation efficiency mapping, and delimiting a response level according to the activation delay time to generate layered repair configuration; activation delay evaluation is conducted on layered repair configuration to determine a preferred activation mode, dynamic activation characteristics are extracted based on optimal activation time window data to form an intervention execution sequence, a skeletal muscle repair execution instruction is output in combination with an exercise prescription parameter table, and dynamic collaborative adaptation of satellite cell repair state monitoring and training scheme parameters is achieved.

The disclosure relates to methods for treating cancer or selecting subjects for cancer treatment using low PD-L1 expression as a patient biomarker prior to treatment.

Disclosed herein are biomarkers that correlate with responses to an anti-ILT4 and anti-PD-1 combination therapy. A biomarker that can differentiate responders from non-responders to this combination therapy can potentially be used to select human subjects who have a higher probability to benefit from such a combination therapy. In one embodiment, a combined positive score (CPS) for PD-L1 expression in a tumor sample from a human subject is used as a biomarker to differentiate a responder from a non-responder to an anti-ILT4 and anti-PD-1 combination therapy. In another embodiment, a T-cell–inflamed gene expression profile (TcellinfGEP) score is used as a biomarker to differentiate a responder from a non-responder to an anti-ILT4 and anti-PD-1 combination therapy.

In alternative embodiments, there is provided an immunohistochemistry (IHC) method for determining and reproducibly scoring the nuclear expression level of protein Ki-67 (also known as MKI67) in tissue samples.In alternative embodiments, there is provided a method for diagnosing, treating, or improving cancer or tumor, or assessing the risk of its recurrence, using the IHC method provided herein.In alternative embodiments, there is provided a kit, which includes components and instructions for carrying out the method provided herein.

The invention provides diagnostic methods for identifying individuals having a lung cancer (e.g., NSCLC) suitable for treatment a treatment regimen that includes a PD-1 axis binding antagonist (e.g., atezolizumab) after adjuvant therapy (e.g., after a platinum-based adjuvant therapy) and therapeutic methods for treating lung cancer (e.g., NSCLC) in an individual identified as one who may benefit from treatment with a treatment regimen that includes a PD-1 axis binding antagonist (e.g., atezolizumab) to the individual following an adjuvant therapy (e.g., after a platinum-based adjuvant therapy). Also provided are compositions (e.g., a PD-1 axis binding antagonist (e.g., atezolizumab), pharmaceutical compositions thereof, assays thereof, kits thereof, and articles of manufacture thereof) for use in identifying patients suitable for treatment and for treating lung cancer (e.g., NSCLC) in an identified individual.

A method to produce a rapid immunohistochemical detection of an antigen from a biological sample is provided. Preferably, the method may be used for rapid immunohistochemical staining of a biological sample that allows completion of the staining process in less than ten minutes, such as during a cancer removal procedure. Preferably, the method may include the steps of: depositing a section of the biological sample on a slide; permeabilizing the section of the biological sample; incubating the section of the biological sample with a secondary antibody having a detectable label; removing unbound secondary antibody from the section of the biological sample; mounting the section of the biological sample; and detecting secondary antibody bound to the section of the biological sample.

Provided are an antibody and an antigen-binding fragment that specifically bind to Nectin-4, and a test kit containing the antibody or the antigen-binding fragment. Also provided are a nucleic acid encoding the antibody, a host cell containing the nucleic acid, and a method for preparing the antibody. Also provided are uses of the antibody specifically binding to Nectin-4 in diagnosis and prognosis.

The present disclosure relates to an engineered M13 bacteriophage displaying on its surface an amyloid producing peptide motif from amyloid beta 42 (A [beta] 42). The present disclosure also relates to the use of the disclosed engineered M13 bacteriophage for detecting and preventing aggregation of early substances of A [beta] (i.e. Oligomeric and fibrillar A [beta]) to promote inhibition of the progression of Alzheimer's disease and thus contribute to the treatment of such neurodegenerative disorders.

The present application describes a method for reducing background fluorescence in single molecule fluorescence in situ hybridization applications, wherein first Sudan Black B is applied to formalin-fixed, paraffin-embedded tissue sections and thereafter the single molecule fluorescence in situ hybridization application is carried out. Furthermore, there is described the use of Sudan Black B for reducing background fluorescence in single molecule fluorescence in situ hybridization applications.

The invention discloses a method for improving the dispersion degree of a sample spot edge of a liquid quality control product, which comprises the following steps: pretreating an EP tube loaded with the liquid quality control product: soaking the EP tube in a surfactant solution, directly draining water, and completely drying in a drying oven; the surfactant solution is one of a Tween-20 solution with the volume concentration of 1%-12%, a Tween-80 solution with the volume concentration of 2%-15% and a Triton-100 solution with the volume concentration of 5%-20%. The pre-treated EP tube is used for loading the liquid quality control product, so that the'coffee ring 'phenomenon can be eliminated in the subsequent sample application process of the liquid quality control product, the quality control product is dispersed more uniformly, the diameter of a sample application spot is not obviously influenced under treatment of different concentrations, and the treated liquid quality control product has the advantages of uniform sample application spot diameter and high quality. The subsequent immunohistochemical staining performance of the liquid quality control product is not influenced.

The invention provides diagnostic methods for identifying individuals having a lung cancer (e.g., NSCLC) suitable for treatment a treatment regimen that includes a PD-1 axis binding antagonist (e.g., atezolizumab) after adjuvant therapy (e.g., after a platinum-based adjuvant therapy) and therapeutic methods for treating lung cancer (e.g., NSCLC) in an individual identified as one who may benefit from treatment with a treatment regimen that includes a PD-1 axis binding antagonist (e.g., atezolizumab) to the individual following an adjuvant therapy (e.g., after a platinum-based adjuvant therapy). Also provided are compositions (e.g., a PD-1 axis binding antagonist (e.g., atezolizumab), pharmaceutical compositions thereof, assays thereof, kits thereof, and articles of manufacture thereof) for use in identifying patients suitable for treatment and for treating lung cancer (e.g., NSCLC) in an identified individual.

Disclosed are methods of treating of a subject having cancer comprising applying an alternating electric field to a target site of the subject for a period of time, wherein the target site comprises one or more cancer cells, wherein the subject has an isocitrate dehydrogenase mutation (IDHmut). Disclosed are methods of treating a subject comprising identifying a subject with an IDHmut; and applying an alternating electric field to a target site of the subject for a period of time, wherein the target site comprises one or more cancer cells.

The present disclosure provides methods and systems for predicting a subject's diagnostic status with respect to a disease or disorder. The method may comprise staining a tooth, hair, or nail sample of the subject to produce a stained tooth sample, analyzing a fluorescence intensity spatially across the stained tooth, hair, or nail sample, and predicting a subject's diagnostic status with respect to a disease or disorder based at least in part on the analysis of the fluorescence intensity.

The present disclosure relates to an engineered M13 bacteriophage displaying amyloidogenic peptide motifs from amyloid beta 42 (Aβ42) at its surface. The present disclosure further relates to the use of the disclosed engineered M13 bacteriophage for detecting early species of Aβ, namely oligomeric and fibrillar Aβ, and preventing its aggregation promoting the inhibition of the progression of Alzheimer's disease and thus contributing to the treatment of this neurodegenerative disorder.

The invention relates, in part, to methods and compounds for ultrastructure membrane expansion microscopy (umExM), which permits high-resolution visualization of membrane ultrastructure using light microscopy.

The invention relates to the technical field of immune globulin, in particular to an anti-gastrin antibody and a hybridoma cell strain and application thereof. The invention provides an anti-gastrin antibody, and also provides a hybridoma cell strain OTI3D11, and the preservation number of the hybridoma cell strain is CGMCC (China General Microbiological Culture Collection Center) No.46359. The invention also provides an anti-gastrin antibody and a hybridoma cell strain OTI3D11. According to the present invention, the hybridoma cell strain OTI3D11 can stably secrete the anti-gastrin monoclonal antibody, and can specifically bind to the Gastrin protein (especially G-17), such that the immunodetection of the hybridoma cell strain OTI3D11 has specificity and sensitivity, and the hybridoma cell strain OTI3D11 can be suitable for the labeling of the Gastrin protein in tissue cells.

A method and apparatus for labeling a tissue section is provided. In certain aspects, the methods comprise labeling a tissue sample via a plurality of immunohistochemistry (IHC) assays for detection of markers for characterization of a cancer origin in an individual having a cancer of unknown primary (CUP). The disclosed IHC assays employ chromogen-based detection methods for improved sample efficiency and visualization of biomarkers. Further disclosed is an apparatus for carrying out the disclosed methods.

A method for identifying, prior to treatment, cancer patients who respond to anti-CLEVER-1 therapy, which includes administration of an agent capable of binding to common lymphatic endothelial and vascular endothelial receptor-1 (CLEVER-1) in a patient. In this method, the presence of PD-L1-expressing cells and CLEVER-1-expressing cells is detected in a tumor sample obtained from a cancer patient by immunohistochemical staining with a PD-L1-specific antibody and a mouse monoclonal IgG2a kappa STAB-1 antibody (clone 4G9), and the ratio of PD-L1-expressing cells from the total amount of viable cells present in the stained sample and the ratio of CLEVER-1-expressing cells within the tumor from the total amount of viable tumor cells present in the stained sample are calculated. A tumor sample with a low ratio of PD-L1-expressing cells or no PD-L1-expressing cells and a significant proportion of CLEVER-1-expressing cells within the tumor indicates that the cancer patient is responsive to anti-CLEVER-1 therapy.

The present disclosure relates to an engineered M13 bacteriophage displaying amyloidogenic peptide motifs from amyloid beta 42 (Aβ42) at its surface. The present disclosure further relates to the use of the disclosed engineered M13 bacteriophage for detecting early species of Aβ, namely oligomeric and fibrillar Aβ, and preventing its aggregation promoting the inhibition of the progression of Alzheimer's disease and thus contributing to the treatment of this neurodegenerative disorder.

This invention discloses an antibody (YWHG-4) against HLA-G isoform molecules HLA-G1, HLA-G4, and HLA-G5, and its uses. The antibody (YWHG-4) is produced from a hybridoma with accession number CCTCC NO:2021204, using the antigenic peptide (RGYYNQSEASSHTLQWMIGC) of amino acid position 106-126 of the HLA-G molecule heavy chain as the immunogen. This invention provides the nucleotide encoding the YWHG-4 antibody and its encoding amino acid sequence. Furthermore, this invention provides the uses of the YWHG-4 antibody for the detection of HLA-G isoform molecules HLA-G1, HLA-G4, and HLA-G5 using Western blotting, immunohistochemistry, ELISA, and flow cytometry.

The present invention provides anti-carcinoembryonic antigen (CEA) antibodies for use in detecting CEA, treating disorders associated with CEA expression, diagnosing cancers characterized by aberrant CEA expression, and predicting the efficacy of cancer chemotherapy. Anti-CEA antibodies, antibody fragments, monoclonal antibodies, antibody conjugates, compositions comprising the described antibodies, and methods of their use are provided.

The invention relates, in part, to methods and compounds for ultrastructure membrane expansion microscopy (umExM), which permits high-resolution visualization of membrane ultrastructure using light microscopy.

The present disclosure provides an antibody for predicting breast cancer prognosis and a nucleic acid encoding sequence thereof, and uses of the same. The antibody for predicting breast cancer prognosis of the present disclosure achieves the effect of predicting breast cancer prognosis through various efficacy experiments.

Provided are methods for treating cancer by converting tumor-resident macrophages to a hybrid M1 / M2 macrophage phenotype, which has attributes that are advantageous for cancer therapy. Hybrid markers (lower than M2 and higher than M1) include SPP1, CD209, and CD206, and inducible markers include MERTK, C1QC, IFNa, IFNb, CXCL10, 4-1BBL, and MYC. The method includes administering a therapeutic agent that achieves the phenotype conversion. The therapeutic agent, such as a delivery vehicle that includes an immunostimulatory bacterium with genomic modifications, is designed to inhibit type I IFN by not inducing or resulting in sufficient TLR2, TLR4, TLR5 responses. The therapeutic agent also encodes a payload that encodes an immunostimulatory protein, e.g., a cytokine, and a modified intracytoplasmic DNA / RNA sensor that constitutively induces type I IFN, such as a modified STING protein. The combination of the properties of the payload immunostimulatory protein and the therapeutic delivery vehicle, when administered, results in macrophages with a hybrid phenotype. The therapeutic agent is administered to a subject identified as having a tumor that contains proliferating M2 macrophages.

The present invention relates to methods and systems for detecting one or more analytes in a sample and / or for classifying a sample. In particular, the present invention relates to methods and systems which can be used to detect the analytes in real time and which rely on flowing through a microfluidic device one or more types of sensor molecule each comprising a domain that binds one or more analytes, a chemiluminescent donor domain and an acceptor domain, wherein the separation and relative orientation of the chemiluminescent donor domain and the acceptor domain, in the presence and / or absence of analyte is within ± 50% of the Forster distance.

Disclosed in the present invention are a monoclonal antibody (YWHG-4) against HLA-G isoforms (HLA-G1, HLA-G4, HLA-G5) and use thereof. The antibody (YWHG-4) is produced by the hybridoma deposited under CCTCC NO: 2021204, and an antigenic peptide (RGYYNQSEASSHTLQWMIGC) of amino acid sequences at positions 106-126 of a heavy chain of HLA-G molecules is used as an immunogen. Provided in the present invention are a nucleotide encoding the YWHG-4 antibody of the present invention and an encoded amino acid sequence thereof. Further provided in the present invention is use of the YWHG-4 antibody in the detection of the HLA-G isoforms (HLA-G1, HLA-G4, HLA-G5) by means of immunoblotting, immunohistochemistry, ELISA and flow cytometry.